Product Highlight - Dupixent

First and Only Biologic Therapy that specifically targets IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation (including Atopic Dermatitis and Asthma)^1,2
Now locally approved for:
- Adult & adolescent (aged 12-17) patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy¹
- An add-on maintenance treatment for patients (12+ years) with inadequately controlled severe asthma with type 2 inflammation¹

References:
1. DUPIXENT Summary of Product Characteristics. May 2020.
2. Gandhi NA et al. Nature Rev Drug Disc 2016; 15: 35–50.

MAT-HK-2000318-1.0-08/2020